{"id":83,"date":"2026-07-28T07:37:09","date_gmt":"2026-07-28T07:37:09","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=83"},"modified":"2026-07-28T07:37:09","modified_gmt":"2026-07-28T07:37:09","slug":"molecular-glues-the-one-click-way-to-delete-a-disease-protein","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/molecular-glues-the-one-click-way-to-delete-a-disease-protein\/","title":{"rendered":"Molecular Glues: The &#8220;One-Click&#8221; Way to Delete a Disease Protein"},"content":{"rendered":"\n<p><em>How a single small molecule can staple two proteins together and send one of them to the cellular shredder \u2014 the mechanism, the medicinal-chemistry logic, and a worked synthesis of the archetypal drug.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Why &#8220;glue&#8221; is the right word<\/h2>\n\n\n\n<p>For a century, small-molecule drugs did essentially one thing: they sat in a pocket of a target protein and&nbsp;<em>blocked<\/em>&nbsp;it. This is&nbsp;<strong>occupancy-driven pharmacology<\/strong>&nbsp;\u2014 the drug has to be present, bound, and outcompeting the substrate to have any effect. It also means the target has to&nbsp;<em>have<\/em>&nbsp;a druggable pocket in the first place, which roughly 80% of the proteome does not.<\/p>\n\n\n\n<p><strong>Molecular glue degraders (MGDs)<\/strong>&nbsp;rewrite that contract. Instead of inhibiting a protein, a molecular glue is a small molecule that sits at the&nbsp;<em>interface<\/em>&nbsp;between two proteins that would normally never touch \u2014 one of them an&nbsp;<strong>E3 ubiquitin ligase<\/strong>&nbsp;(the cell&#8217;s &#8220;tag-for-disposal&#8221; machine) and the other a&nbsp;<strong>disease-driving target<\/strong>. The glue creates a brand-new, complementary protein\u2013protein surface that neither protein has any natural affinity for. Once glued together, the ligase tags the target with ubiquitin, and the 26S proteasome destroys it.<\/p>\n\n\n\n<p>The consequences are profound:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>It is event-driven, not occupancy-driven.<\/strong>\u00a0The glue doesn&#8217;t need to stay bound. It catalyzes one tagging event, the target is degraded, and the glue is released to do it again \u2014\u00a0<strong>catalytic, sub-stoichiometric<\/strong>\u00a0pharmacology. One molecule can eliminate many copies of a target.<\/li>\n\n\n\n<li><strong>It removes the entire protein<\/strong>, not just one active site \u2014 so scaffolding functions, allosteric functions, and protein\u2013protein interactions of the target all disappear together.<\/li>\n\n\n\n<li><strong>It can drug the &#8220;undruggable.&#8221;<\/strong>\u00a0The target no longer needs an enzymatic pocket; it only needs a surface the glue-loaded ligase can grip.<\/li>\n<\/ul>\n\n\n\n<p>This is the sense in which people describe molecular glues as a&nbsp;<strong>&#8220;one-click&#8221; modality<\/strong>: a single, orally available, drug-like small molecule triggers the complete elimination of a pathogenic protein, using machinery the cell already owns.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">2. The mechanism of action, step by step<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"433\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1024x433.png\" alt=\"\" class=\"wp-image-84\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1024x433.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-300x127.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-768x325.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1536x650.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2048x866.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"http:\/\/localhost:8765\/api\/artifacts\/c23dedeb-6dfe-4cb2-9161-85dd4b476851?v=b497fc3b-8146-4a26-a555-30f5ca475329\" alt=\"Molecular glue mechanism of action: (A) the glue nucleates a ternary complex between the CRBN E3 ligase and the IKZF neosubstrate; (B) ubiquitin transfer marks the substrate for proteasomal degradation.\"\/><\/figure>\n\n\n\n<p>The best-understood molecular glues hijack&nbsp;<strong>cereblon (CRBN)<\/strong>, the substrate-recognition subunit of the CRL4 (Cullin-4 RING) E3 ubiquitin ligase complex.<\/p>\n\n\n\n<p><strong>Step 1 \u2014 The glue docks into cereblon.<\/strong>&nbsp;Each of these drugs carries a&nbsp;<strong>glutarimide ring<\/strong>&nbsp;(a 2,6-dioxopiperidine). This ring is the&nbsp;<em>degron mimic<\/em>: it plugs into CRBN&#8217;s shallow&nbsp;<strong>tri-tryptophan pocket<\/strong>&nbsp;exactly where CRBN&#8217;s natural degron substrates would bind. This is highlighted in gold in every structure below.<\/p>\n\n\n\n<p><strong>Step 2 \u2014 A new surface is created.<\/strong>&nbsp;With the glutarimide buried, the rest of the drug \u2014 the&nbsp;<strong>phthalimide or isoindolinone &#8220;hotspot&#8221;<\/strong>&nbsp;\u2014 protrudes from CRBN&#8217;s surface and reshapes it. This modified surface is now complementary to a&nbsp;<strong>\u03b2-hairpin &#8220;G-loop&#8221; degron<\/strong>&nbsp;found on certain transcription factors.<\/p>\n\n\n\n<p><strong>Step 3 \u2014 The neosubstrate is recruited.<\/strong>&nbsp;Proteins bearing that structural degron \u2014 most famously the zinc-finger transcription factors&nbsp;<strong>IKZF1 (Ikaros)<\/strong>&nbsp;and&nbsp;<strong>IKZF3 (Aiolos)<\/strong>&nbsp;\u2014 are drawn into a&nbsp;<strong>ternary complex<\/strong>&nbsp;(CRBN \u2022 glue \u2022 neosubstrate). Crucially, CRBN and IKZF1\/3 have&nbsp;<em>no<\/em>&nbsp;natural affinity for one another; the glue manufactures the interaction. These recruited targets are called&nbsp;<strong>neosubstrates<\/strong>&nbsp;because they were never natural substrates of the ligase.<\/p>\n\n\n\n<p><strong>Step 4 \u2014 Ubiquitin transfer.<\/strong>&nbsp;Now held in place, the neosubstrate is presented to the CRL4 machinery&#8217;s E2 ubiquitin-conjugating enzyme, which builds a&nbsp;<strong>polyubiquitin chain<\/strong>&nbsp;on it.<\/p>\n\n\n\n<p><strong>Step 5 \u2014 Proteasomal degradation.<\/strong>&nbsp;The polyubiquitinated neosubstrate is recognized and shredded by the&nbsp;<strong>26S proteasome<\/strong>. The glue and CRBN are released to recycle.<\/p>\n\n\n\n<p><strong>Step 6 \u2014 Downstream collapse.<\/strong>&nbsp;In multiple myeloma, losing IKZF1\/3 collapses the downstream oncogenic program \u2014 chiefly&nbsp;<strong>IRF4 and MYC<\/strong>&nbsp;\u2014 killing the tumor cell, while simultaneously de-repressing T-cell and NK-cell immunity. This dual cytotoxic-plus-immunomodulatory action is the therapeutic signature of the class.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">3. The medicinal-chemistry story: one scaffold, four decades<\/h2>\n\n\n\n<p>The remarkable thing is that this entire class descends from a single, notorious molecule. The structural evolution below tells the story \u2014 and note the&nbsp;<strong>gold glutarimide degron is conserved in every single one<\/strong>. Medicinal chemistry has kept the CRBN-binding &#8220;anchor&#8221; fixed and re-engineered everything else to tune&nbsp;<em>which<\/em>neosubstrates get recruited and&nbsp;<em>how efficiently<\/em>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"218\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1-1024x218.png\" alt=\"\" class=\"wp-image-85\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1-1024x218.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1-300x64.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1-768x164.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1-1536x327.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-1.png 1550w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"http:\/\/localhost:8765\/api\/artifacts\/a02bd438-4293-4427-aebc-6c43c0ea8483?v=63b5e00e-ead3-493e-823c-f377ab7183b8\" alt=\"Structural evolution of cereblon molecular glues, from thalidomide through the next-generation CELMoDs mezigdomide and iberdomide. The conserved glutarimide degron (gold) anchors every member to cereblon; the variable &quot;business end&quot; tunes neosubstrate selectivity and degradation efficiency.\"\/><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thalidomide (1957)<\/strong>\u00a0\u2014 Infamous as a sedative that caused severe birth defects (we now know teratogenicity comes from aberrant recruitment of the transcription factor\u00a0<strong>SALL4<\/strong>\u00a0to CRBN). Decades later it was rehabilitated for multiple myeloma and leprosy. The parent glutarimide\u2013phthalimide.<\/li>\n\n\n\n<li><strong>Lenalidomide (2005)<\/strong>\u00a0\u2014 Adds an amino group and converts the phthalimide to an isoindolinone. A blockbuster in multiple myeloma and in\u00a0<strong>del(5q) myelodysplastic syndrome<\/strong>, where it additionally degrades the kinase\u00a0<strong>CK1\u03b1<\/strong>. For years one of the best-selling oncology drugs in the world.<\/li>\n\n\n\n<li><strong>Pomalidomide (2013)<\/strong>\u00a0\u2014 An amino-phthalimide, more potent, for relapsed\/refractory myeloma.<\/li>\n\n\n\n<li><strong>Iberdomide (CC-220) and Mezigdomide (CC-92480)<\/strong>\u00a0\u2014 The\u00a0<strong>CELMoDs<\/strong>\u00a0(Cereblon E3 Ligase Modulating Drugs). These rationally designed, next-generation glues bolt a large &#8220;business end&#8221; (a morpholine- or benzonitrile-piperazine arm through a benzyl-ether linker) onto the isoindolinone. They bind CRBN with far higher affinity than lenalidomide and drive\u00a0<strong>faster, deeper degradation<\/strong>\u00a0of IKZF1\/3 \u2014 engineered specifically to overcome resistance in heavily pretreated patients.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The frontier clinical example: mezigdomide<\/h3>\n\n\n\n<p>Mezigdomide is the most advanced next-generation molecular glue. In March 2026, BMS announced&nbsp;<strong>positive interim Phase III results<\/strong>&nbsp;from the&nbsp;<strong>SUCCESSOR-2 trial<\/strong>&nbsp;(NCT05552976): oral mezigdomide plus carfilzomib and dexamethasone (MeziKd) met its primary endpoint, roughly doubling median progression-free survival to&nbsp;<strong>18.0 months versus 8.3 months<\/strong>&nbsp;for carfilzomib\/dexamethasone alone in relapsed\/refractory myeloma, with data being shared with global health authorities. Its sister CELMoD&nbsp;<strong>iberdomide<\/strong>&nbsp;is a step further along the regulatory path: the FDA accepted its NDA (iberdomide + daratumumab + dexamethasone) in February 2026 with&nbsp;<strong>Breakthrough Therapy Designation and Priority Review<\/strong>, based on the Phase III EXCALIBER-RRMM trial (MRD-negativity endpoint), and a&nbsp;<strong>PDUFA target date of August 17, 2026<\/strong>&nbsp;\u2014 putting iberdomide in position to become the&nbsp;<strong>first approved CELMoD<\/strong>. Both illustrate the payoff of the &#8220;keep the degron, redesign the surface&#8221; strategy: same one-click mechanism, dramatically improved degradation kinetics.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">4. A worked synthesis: lenalidomide in three steps<\/h2>\n\n\n\n<p>To make the chemistry concrete, here is the classic manufacturing route to&nbsp;<strong>lenalidomide<\/strong>&nbsp;\u2014 the cleanest teaching example of how you actually&nbsp;<em>build<\/em>&nbsp;a molecular glue. The synthesis is elegantly short because the molecule is small and modular: you build the substrate-recruiting&nbsp;<strong>isoindolinone<\/strong>&nbsp;half and the CRBN-binding&nbsp;<strong>glutarimide<\/strong>&nbsp;half, and stitch them together in one cyclization.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"279\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-1024x279.png\" alt=\"\" class=\"wp-image-86\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-1024x279.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-300x82.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-768x209.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-1536x418.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/07\/image-2-2048x558.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"http:\/\/localhost:8765\/api\/artifacts\/c92ff5e2-bac9-460d-9c4b-f18b8acaff3c?v=31f9fdd1-3fe9-439e-9311-d3b9da08f90a\" alt=\"Three-step synthesis of lenalidomide: (1) benzylic bromination of methyl 2-methyl-3-nitrobenzoate; (2) cyclative N-alkylation with 3-aminopiperidine-2,6-dione to install the glutarimide degron and close the isoindolinone ring; (3) catalytic hydrogenation of the nitro group to the aniline that defines lenalidomide.\"\/><\/figure>\n\n\n\n<p><strong>Step 1 \u2014 Benzylic bromination.<\/strong>&nbsp;Methyl 2-methyl-3-nitrobenzoate is treated with&nbsp;<strong>N-bromosuccinimide (NBS)<\/strong>&nbsp;and the radical initiator&nbsp;<strong>AIBN<\/strong>&nbsp;in acetonitrile at 55\u201375 \u00b0C. This installs a bromide on the benzylic methyl group, giving methyl 2-(bromomethyl)-3-nitrobenzoate \u2014 a reactive electrophile primed for the ring-forming step. (The nitro group is carried through deliberately; it becomes the drug&#8217;s defining amine at the very end.)<\/p>\n\n\n\n<p><strong>Step 2 \u2014 Cyclative N-alkylation (the key bond-forming step).<\/strong>&nbsp;The bromomethyl ester is condensed with&nbsp;<strong>3-aminopiperidine-2,6-dione hydrochloride<\/strong>&nbsp;\u2014 this is the pre-formed&nbsp;<strong>glutarimide degron<\/strong>&nbsp;\u2014 using&nbsp;<strong>triethylamine<\/strong>&nbsp;as base in&nbsp;<strong>DMSO<\/strong>&nbsp;at 50\u201355 \u00b0C. The primary amine of the glutarimide does double duty: it displaces the benzylic bromide (N-alkylation)&nbsp;<em>and<\/em>&nbsp;then cyclizes onto the ester carbonyl (lactam formation), closing the five-membered&nbsp;<strong>isoindolinone<\/strong>&nbsp;ring in a single operation. The product, 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione, already has the complete molecular-glue architecture \u2014 degron plus substrate-recruiting head \u2014 assembled.<\/p>\n\n\n\n<p><strong>Step 3 \u2014 Nitro reduction.<\/strong>&nbsp;Finally,&nbsp;<strong>catalytic hydrogenation<\/strong>&nbsp;(H\u2082 at 60\u2013100 psi over 10%&nbsp;<strong>Pd\/C<\/strong>, in ammonia-buffered NMP) reduces the aromatic nitro group to the aromatic amine. That newly unveiled&nbsp;<strong>4-amino<\/strong>&nbsp;group is precisely what distinguishes lenalidomide from thalidomide, and the run is capped by recrystallization to API-grade purity.<\/p>\n\n\n\n<p>Three steps, cheap reagents, one strategic cyclization \u2014 a reminder that these transformative drugs are, chemically, remarkably accessible.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">5. Why the field is exploding<\/h2>\n\n\n\n<p>Molecular glues combine the drug-like virtues of ordinary small molecules \u2014 oral dosing, cell permeability, straightforward synthesis (as above) \u2014 with the catalytic, complete-knockout power of targeted protein degradation. Compared with the other major degrader modality,&nbsp;<strong>PROTACs<\/strong>&nbsp;(bifunctional molecules that tether a target ligand to an E3 ligand), glues are far smaller and more &#8220;natural&#8221; as drugs because they don&#8217;t require a pre-existing high-affinity ligand for the target \u2014 they&nbsp;<em>induce<\/em>&nbsp;the interaction from a modest starting surface.<\/p>\n\n\n\n<p>That is why the pipeline has erupted well beyond the CRBN\/IMiD franchise:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beyond IKZF1\/3:<\/strong>\u00a0rationally designed glues now degrade\u00a0<strong>CK1\u03b1<\/strong>,\u00a0<strong>GSPT1<\/strong>,\u00a0<strong>RBM39<\/strong>,\u00a0<strong>HuR<\/strong>, and a growing list of previously &#8220;undruggable&#8221; targets.<\/li>\n\n\n\n<li><strong>Beyond cereblon:<\/strong>\u00a0newer programs recruit other E3 ligases (DCAF15, DDB1, \u03b2-TrCP and others), and even\u00a0<strong>non-degrading<\/strong>\u00a0glues that simply reshape protein function.<\/li>\n\n\n\n<li><strong>Beyond oncology:<\/strong>\u00a0autoimmune disease (e.g., iberdomide in lupus), neurodegeneration, and rare disease are all now in scope.<\/li>\n<\/ul>\n\n\n\n<p>With three approved IMiD glues, next-generation CELMoDs at the threshold of approval, and dozens of first-in-class degraders in trials, molecular glue technology has moved from a serendipitous accident (thalidomide) to a deliberate, programmable strategy for deleting disease proteins \u2014 one click at a time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>How a single small molecule can staple two proteins together and send one of them to the cellular shredder \u2014 the mechanism, the medicinal-chemistry logic, and a worked synthesis of the archetypal drug. 1. Why &#8220;glue&#8221; is the&hellip;<\/p>\n","protected":false},"author":1,"featured_media":87,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-83","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/83","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=83"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/83\/revisions"}],"predecessor-version":[{"id":88,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/83\/revisions\/88"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/87"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=83"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=83"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=83"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}